Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01138111|
Recruitment Status : Completed
First Posted : June 7, 2010
Results First Posted : June 25, 2014
Last Update Posted : June 25, 2014
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Alzheimer Disease Amyloid Beta-Protein||Drug: Florbetaben (BAY94-9172)||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||45 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||ß-amyloid Imaging With BAY94-9172 Positron Emission Tomography for Early Detection of Alzheimer's Disease in Patients With Mild Cognitive Impairment|
|Study Start Date :||June 2008|
|Actual Primary Completion Date :||December 2011|
|Actual Study Completion Date :||December 2011|
|Experimental: Arm 1||
Drug: Florbetaben (BAY94-9172)
single 300 megabecquerel (MBq) intravenous injection 2 mL to 10 mL, at baseline, at 12 and 24 months
- Quantitative Assessment of Neocortical SUVRs (Mean Standard Uptake Value Ratios) as a Measure of Florbetaben Uptake [ Time Frame: 1 scanning period post injection to be evaluated at baseline, 12 months and 24 months ]Mean SUVRs were calculated for subjects who did and did not progress to Alzheimer's Disease (AD) during the study for each PET scan time point (baseline, 12 and 24 months)
- Number of Normal and Abnormal Scans in Patients With MCI Progressing to AD and Those Who do Not Progress Based on a Threshold of Neocortical SUVR=1.4 [ Time Frame: 1 scanning period post injection to be evaluated at baseline, at 12 months and at 24 months ]This outcome measure showed the number of abnormal scans in subjects with MCI progressing to AD and those who did not progress compared to subjects with normal scans that did not progress and those who did progress.
- Number and Proportion of Normal and Abnormal Scans Based on Brain ß-amyloid Plaque Load (BAPL) in Subjects With MCI Converting to AD and Those Who do Not Progress [ Time Frame: 2 scanning periods post injection to be evaluated each at baseline, at 12 months, and at 24 months ]At each study time point (baseline, 12 months and 24 months) PET images were obtained at 45 min and again at 90 post injection. These images were assigned a BAPL score of 1, 2 or 3 based on the reader's evaluation of the scan. A BAPL scores of 1 was considered normal, and scores of 2 and 3 were considered abnormal. These scores were compared to subjects clinical diagnosis for AD at the end of the study follow up period.
- Sensitivity/Specificity/Negative Predictive Value (NPV)/Positive Predictive Value (PPV) at Baseline, 12, and 24 Months in the Detection of Significant Brain ß-amyloid Plaque Load in Patients With MCI Progressing to AD Compared to Those Who do Not Progress [ Time Frame: 2 scanning periods post injection to be evaluated at baseline ]
Sensitivity, specificity, NPV and PPV were measured based on subject BAPL scores by time point and imaging window, compared to clinical diagnosis of AD during the study period. A BAPL score of 1 was considered negative for the presence of beta-amyloid, and scores of 2 and 3 were considered positive.
For this study, sensitivity was defined as the percentage of subjects with a clinical diagnosis of AD who also had a positive PET scan (BAPL score of 2 or 3) at the respective time point.
Specificity was defined as the percentage of subjects with a clinical diagnosis of non-AD who also had a negative PET scan (BAPL score of 0 or 1) at the respective time point.
PPV was defined as the probability that a subject with a positive PET scan would have a clinical diagnosis of AD sometime during the 2 year follow up period.
NPV was defined as the probability that a subject with a negative PET scan would not have a clinical diagnosis of AD at any point during the 2 year follow up period.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||60 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Presence of MCI defined as abnormal cognition on objective testing in the absence of dementia or significant functional loss.
- Absence of systemic or other neurological disease that may contribute to cognitive impairment or prevent follow-up over two years.
- Able to give written informed consent.
- Age >/= 60 years of age
- >/= 7 years of education
- Mini mental state examination (MMSE) score < 24 at baseline
- Clinical dementia rating (CDR) score > 0.5 at baseline
- Patients who receive regular medication of drugs which may adversely impact cognition (e.g. tricyclic antidepressants, antipsychotics and/or large doses of hypnotics or anxiolytics)
- Existing or history of cancer
- History of severe head trauma, brain surgery or intracranial hematoma with permanent brain lesion
- Lifetime history of major affective disorder, schizophrenia, or schizo-affective disorder
- Contraindications to MRI (Magnetic resonance imaging)
- Relevant history, physical or imaging findings of neurological disease other than MCI and mild depression
- History of severe anaphylactic reaction or high risk of allergic reaction to drugs
- Patient has received another investigational drug in the preceding 14 days
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01138111
|Heidelberg, Victoria, Australia, 3084|
|Study Director:||Bayer Study Director||Bayer|
|Responsible Party:||Life Molecular Imaging SA|
|Other Study ID Numbers:||
|First Posted:||June 7, 2010 Key Record Dates|
|Results First Posted:||June 25, 2014|
|Last Update Posted:||June 25, 2014|
|Last Verified:||May 2014|
Central Nervous System Diseases
Nervous System Diseases